Sirtris Pharmaceuticals (SIRT)' Review of Sirtuin Therapeutics for Diseases of Aging in the Journal Nature Reviews Drug Discovery
10/1/2008 9:01:06 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled “SIRTUINS – Novel Therapeutic Targets to Treat Age-Associated Diseases,” the review appears in today’s issue of the journal Nature Reviews Drug Discovery.
comments powered by